23385102|t|Factors predisposing to coma and delirium: fentanyl and midazolam exposure; CYP3A5, ABCB1, and ABCG2 genetic polymorphisms; and inflammatory factors.
23385102|a|BACKGROUND: Delirium and sedative-induced coma are described as incremental manifestations of cerebral dysfunction. Both may be associated with sedative or opiate doses and pharmacokinetic or pharmacogenetic variables, such as drug plasma levels (exposure), drug metabolism, and/or their transport across the blood-brain barrier. OBJECTIVES: To compare biological and drug treatment characteristics in patients with coma and/or delirium while in the ICU. PATIENTS AND MEASUREMENTS: In 99 patients receiving IV fentanyl, midazolam, or both, we evaluated drug doses, covariates likely to influence drug effects (age, body mass index, and renal and hepatic dysfunction); delirium risk factors; concomitant administration of CYP3A and P-glycoprotein substrates/inhibitors; ABCB1, ABCG2, and CYP3A5 genetic polymorphisms; and fentanyl and midazolam plasma levels. Delirium and coma were evaluated daily. In patients with only coma (n=15), only delirium (n=7), and neither ever (n=14), we measured plasma levels of tumor necrosis factor-alpha, interleukin (IL)-1beta, IL-1RA, IL-6, IL-8, IL-10, IL-17,macrophage inflammatory protein-1beta, and monocyte chemotactic protein-1. RESULTS: Time to first coma was associated with fentanyl and midazolam doses (p=0.03 and p=0.01, respectively). The number of days in coma was associated with the number of days of coadministration of CYP3A inhibitors (r=0.30; p=0.006). Plasma levels of fentanyl were higher in patients with clinical coma (3.7+-4.7 vs. 2.0+-1.8 ng/mL, p=0.0001) as were midazolam plasma levels (1050+-2232 vs. 168+-249 ng/mL, p=0.0001). Delirium occurrence was unrelated to midazolam administration, cumulative doses, or serum levels. Days with delirium were associated with days of coadministration of P-glycoprotein inhibitor (r=0.35; p=0.0004). Delirious patients had higher levels of the inflammatory mediator IL-6 than comatose patients (129.3 vs. 35.0 pg/mL, p=0.05). CONCLUSIONS: Coma is associated with fentanyl and midazolam exposure; delirium is unrelated to midazolam and may be linked to inflammatory status. These data suggest that iatrogenic coma and delirium are not mechanistically linked.
23385102	24	28	coma	Disease	MESH:D003128
23385102	33	41	delirium	Disease	MESH:D003693
23385102	43	51	fentanyl	Chemical	MESH:D005283
23385102	56	65	midazolam	Chemical	MESH:D008874
23385102	76	82	CYP3A5	Gene	1577
23385102	84	89	ABCB1	Gene	5243
23385102	95	100	ABCG2	Gene	9429
23385102	128	140	inflammatory	Disease	MESH:D007249
23385102	162	170	Delirium	Disease	MESH:D003693
23385102	192	196	coma	Disease	MESH:D003128
23385102	244	264	cerebral dysfunction	Disease	MESH:D002547
23385102	306	312	opiate	Chemical	MESH:D053610
23385102	552	560	patients	Species	9606
23385102	566	570	coma	Disease	MESH:D003128
23385102	578	586	delirium	Disease	MESH:D003693
23385102	605	613	PATIENTS	Species	9606
23385102	638	646	patients	Species	9606
23385102	660	668	fentanyl	Chemical	MESH:D005283
23385102	670	679	midazolam	Chemical	MESH:D008874
23385102	786	815	renal and hepatic dysfunction	Disease	MESH:D008107
23385102	818	826	delirium	Disease	MESH:D003693
23385102	871	876	CYP3A	Gene	1576
23385102	881	895	P-glycoprotein	Gene	5243
23385102	919	924	ABCB1	Gene	5243
23385102	926	931	ABCG2	Gene	9429
23385102	937	943	CYP3A5	Gene	1577
23385102	971	979	fentanyl	Chemical	MESH:D005283
23385102	984	993	midazolam	Chemical	MESH:D008874
23385102	1009	1017	Delirium	Disease	MESH:D003693
23385102	1022	1026	coma	Disease	MESH:D003128
23385102	1052	1060	patients	Species	9606
23385102	1071	1075	coma	Disease	MESH:D003128
23385102	1089	1097	delirium	Disease	MESH:D003693
23385102	1159	1186	tumor necrosis factor-alpha	Gene	7124
23385102	1188	1210	interleukin (IL)-1beta	Gene	3553
23385102	1212	1218	IL-1RA	Gene	3557
23385102	1220	1224	IL-6	Gene	3569
23385102	1226	1230	IL-8	Gene	3576
23385102	1232	1237	IL-10	Gene	3586
23385102	1239	1282	IL-17,macrophage inflammatory protein-1beta	Gene	3605;9560
23385102	1288	1318	monocyte chemotactic protein-1	Gene	6347
23385102	1343	1347	coma	Disease	MESH:D003128
23385102	1368	1376	fentanyl	Chemical	MESH:D005283
23385102	1381	1390	midazolam	Chemical	MESH:D008874
23385102	1454	1458	coma	Disease	MESH:D003128
23385102	1521	1526	CYP3A	Gene	1576
23385102	1574	1582	fentanyl	Chemical	MESH:D005283
23385102	1598	1606	patients	Species	9606
23385102	1621	1625	coma	Disease	MESH:D003128
23385102	1674	1683	midazolam	Chemical	MESH:D008874
23385102	1741	1749	Delirium	Disease	MESH:D003693
23385102	1778	1787	midazolam	Chemical	MESH:D008874
23385102	1849	1857	delirium	Disease	MESH:D003693
23385102	1907	1921	P-glycoprotein	Gene	5243
23385102	1962	1970	patients	Species	9606
23385102	1996	2008	inflammatory	Disease	MESH:D007249
23385102	2018	2022	IL-6	Gene	3569
23385102	2028	2036	comatose	Disease	MESH:D003128
23385102	2037	2045	patients	Species	9606
23385102	2091	2095	Coma	Disease	MESH:D003128
23385102	2115	2123	fentanyl	Chemical	MESH:D005283
23385102	2128	2137	midazolam	Chemical	MESH:D008874
23385102	2148	2156	delirium	Disease	MESH:D003693
23385102	2173	2182	midazolam	Chemical	MESH:D008874
23385102	2204	2216	inflammatory	Disease	MESH:D007249
23385102	2260	2264	coma	Disease	MESH:D003128
23385102	2269	2277	delirium	Disease	MESH:D003693
23385102	Association	MESH:D003128	1576
23385102	Positive_Correlation	MESH:D008874	MESH:D003128
23385102	Positive_Correlation	MESH:D005283	MESH:D003128
23385102	Positive_Correlation	MESH:D053610	MESH:D003128
23385102	Comparison	MESH:D005283	MESH:D008874
23385102	Association	MESH:D053610	MESH:D003693
23385102	Positive_Correlation	MESH:D008874	MESH:D003693

